Results 191 to 200 of about 4,456,677 (340)

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

open access: yesMolecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

open access: yesMolecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen   +12 more
wiley   +1 more source

Proposal and Verification of New Revised Criteria for ABPA/ABPM Diagnosis

open access: yesJournal of Asthma and Allergy
Runjin Cai,1,2,* Huan Ge,1,2,* Bin Liu,3,* Yuling Tang,4,* Jun Wang,5,* Xuemei Chen,1,2 Bing Liu,3,6 Xinyue Hu,1,2 Shuanglinzi Deng,1,2 Hui Li,4 Lixue Dai,5 Jiale Tang,1,2 Chendong Wu,1,2 Xiaoxiao Gong,1,2 Guo Wang,1,2 Xiaozhao Li,2,7
Cai R   +16 more
doaj  

Flu-CNN: identifying host specificity of Influenza A virus using convolutional networks. [PDF]

open access: yesHum Genomics
Hu M   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy